AC Immune SA
AC Immune SA is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is [18F]ACI-19626 PET in TDP-43 Proteinopathies on November 15, 2026. There are 4 upcoming events on record.
Cash runway is approximately 4.7 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 15, 2026 | [18F]ACI-19626 PET in TDP-43 Proteinopathies | Trial Milestone | EARLY_Phase 1 |
| December 15, 2026 | A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors | Trial Milestone | Phase 1 |
| June 15, 2028 | A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease | Trial Milestone | Phase 2 |
| April 15, 2029 | A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) | Trial Milestone | Phase 1/Phase 2 |
Track ACIU alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ACIU in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.